
IGF-1 LR3
Insulin-like Growth Factor 1 Long R3
Potential Benefits
- Extended half-life compared to native IGF-1 due to reduced binding protein interaction
- Research confirms potent mitogenic and anti-apoptotic cellular effects
- May support muscle protein synthesis and nitrogen retention
- Studies suggest potential for nutrient partitioning favoring lean tissue
- Used in cell culture research to promote cell proliferation
Recommended Starting Dose
20-40 mcg subcutaneously (highly experimental; carries significant metabolic risk)
Based on published research protocols. Not a prescription.
Dosing Protocol
Anecdotal protocols describe 20-80 mcg subcutaneously daily, often timed around workouts. Cycles are typically limited to 4-6 weeks due to desensitization concerns and side effect risk. Blood glucose monitoring is strongly recommended. This is one of the higher-risk peptides due to its potent growth and metabolic effects.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Anecdotal reports describe effects on muscle fullness and recovery within 1-2 weeks. Hypoglycemic effects can occur immediately.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Hypoglycemia (significant risk; IGF-1 has insulin-like glucose-lowering effects)
- Potential for uncontrolled cell growth and proliferation
- Joint pain and swelling
- Jaw, hand, and foot growth with chronic use (acromegaloid features)
- Organ enlargement with prolonged high-dose use
- Theoretical and epidemiological concerns about cancer risk with elevated IGF-1
- Gut growth reported anecdotally
- Not manufactured under pharmaceutical quality standards in most cases
More in Growth Hormone

CJC-1295 (no DAC) / Mod GRF 1-29
CJC-1295 without DAC
CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone in a pulsatile fashion, mimicking the body's natural rhythm. It is often paired with a GHRP like Ipamorelin for synergistic effects.

CJC-1295 DAC
CJC-1295 with Drug Affinity Complex
CJC-1295 with DAC is a long-acting GHRH analog that includes a Drug Affinity Complex, which binds to albumin in the blood and extends its half-life to approximately 6-8 days. This results in sustained elevation of growth hormone levels rather than pulsatile release. It was developed by ConjuChem Biotechnologies.

Ipamorelin
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor to stimulate growth hormone release from the pituitary gland. It is considered one of the milder GH secretagogues, producing a targeted GH pulse without significant increases in cortisol, prolactin, or appetite. It is frequently combined with CJC-1295 (no DAC).
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.